Company intelligence / Profile preview

Annoroad Gene Technology

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Annoroad offers validated NGS instruments (e.g. NextSeq 550AR, PacBio Sequel), CFDA-approved NIPT kits and software, a top-3 sequencing service in China, and maintains a proprietary multi-omics clinical database. Clinical sensitivity for Down syndrome detection is >99% per market norms, but specific trial results are not published.

Therapeutic areas: OncologyWomen's HealthHematologyRare Diseases
Modalities: DNA sequencing technologyReagent kitsBioinformatics platform
Industry: Molecular Diagnostics

Partnerships

Illumina (NextSeq 550AR development/China CFDA approval)Pacific Biosciences (Sequel System integration)Alibaba Cloud (SolarGenomics big data platform)

Beyond the preview

Go deeper on Annoroad Gene Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Annoroad Gene Technology.

Explore the full profile